Abstract
The deficiency of conventional drugs that are used in inflammatory rheumatic diseases are not able to prevent from progression of diseases have resulted in the development of new drugs, such as TUMOR Necrosis Factor-α (TNF-α) blocking agents, Interleukin-1 (IL-1) receptor antagonist and Anti-B cell (CD20) antibody. Biologic agents are a clear advancement in drug therapy. These newer agents have mechanisms of action targeted toward specific components of the immune system, which enable them to provide more reliable outcomes with fewer limiting side effects. They are administered subcutaneously and/or intravenously. The goal of the biologic treatment is to slow or block specific components of the immune system and halt tissue destruction.
Keywords: Biologic agents, pharmacokinetic, TNF-α blocking agents, IL-1 receptor antagonist, anti-B cell antibody, T-cell activator, IL-6 inhibitor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: The Pharmacokinetics of Biologic Agents
Volume: 9 Issue: 1
Author(s): Turhan Dost
Affiliation:
Keywords: Biologic agents, pharmacokinetic, TNF-α blocking agents, IL-1 receptor antagonist, anti-B cell antibody, T-cell activator, IL-6 inhibitor
Abstract: The deficiency of conventional drugs that are used in inflammatory rheumatic diseases are not able to prevent from progression of diseases have resulted in the development of new drugs, such as TUMOR Necrosis Factor-α (TNF-α) blocking agents, Interleukin-1 (IL-1) receptor antagonist and Anti-B cell (CD20) antibody. Biologic agents are a clear advancement in drug therapy. These newer agents have mechanisms of action targeted toward specific components of the immune system, which enable them to provide more reliable outcomes with fewer limiting side effects. They are administered subcutaneously and/or intravenously. The goal of the biologic treatment is to slow or block specific components of the immune system and halt tissue destruction.
Export Options
About this article
Cite this article as:
Dost Turhan, The Pharmacokinetics of Biologic Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711700
DOI https://dx.doi.org/10.2174/187152310790711700 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty
Current HIV Research Ubiquitin Ligases as Key Elements for the Modulation of the Immune Response: An Insight in the Pathogenesis of Autoimmunity
Current Rheumatology Reviews Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs
Current Molecular Pharmacology Curcumin Against Malaria: From Traditional Medicine to Development of Synthetic Analogs; A Bioorganic Approach
Current Traditional Medicine Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design Sunitinib in the Treatment of Thyroid Cancer
Current Medicinal Chemistry Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities
Current Molecular Medicine Targeted Therapies and other Agents as First-Line Maintenance and Beyond: Particular Benefit in Pulmonary Adenocarcinoma Patients
Current Medicinal Chemistry Personalized Medicine in Oncology: A Personal View with Myths and Facts
Current Clinical Pharmacology In Vitro Intestinal Co-Culture Cell Model to Evaluate Intestinal Absorption of Edelfosine Lipid Nanoparticles
Current Topics in Medicinal Chemistry Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Circulating Endothelial Progenitor Cells in Tumor Angiogenesis
Current Stem Cell Research & Therapy Oridonin, a Promising Antitumor Natural Product in the Chemotherapy of Hematological Malignancies
Current Pharmaceutical Biotechnology Pharmacogenetics and Inflammatory Bowel Disease
Current Pharmacogenomics and Personalized Medicine N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Metal Allergens of Growing Significance: Epidemiology, Immunotoxicology, Strategies for Testing and Prevention
Inflammation & Allergy - Drug Targets (Discontinued) IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Current Medicinal Chemistry Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease
Current Neuropharmacology